Effect of growth hormone secretagogue LY444711 on IGF-1, growth hormone, and cortisol levels in beagle dogs after one and seven daily oral doses

Drug Development Research

Volumn 49, Issue 4, 2000, Pages 260-265

  Seyler, David E ^a,b   Dodge, Jeffrey A ^a   Osborne, John J ^a   Cox, Karen L ^a   Viswanath, Devanarayan ^a   Wilmot, Anita F ^a   Keaton, M Joni ^a   Heiman, Mark L ^a   Bryant, Henry U ^a   Cutler Jr , Gordon B ^a  

^a ELI LILLY AND COMPANY   (United States)

^b NONE   (United States)

Author keywords

Cortisol; Dog; Growth hormone; IGF 1; Secretagogue

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; GROWTH HORMONE; HYDROCORTISONE; IMIDAZOLE DERIVATIVE; LY 444711; PYRROLIDINE DERIVATIVE; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOG; DRUG ACTIVITY; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; HORMONAL REGULATION; MALE; NONHUMAN;

EID: 0033918166     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/1098-2299(200004)49:4<260::AID-DDR5>3.0.CO;2-6     Document Type: Article

References (20)

1. Abe H, Molitch ME, Van Wyk JJ, Underwood LE. 1983. Human growth hormone and somatomedin C suppress the spontaneous release of growth hormone in unanesthetized rats. Endocrinology 113:1319-1324.
2. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans Automat Control AC 19:716-723.
3. Arvat E, Di Vito L, Lanfranco F, Broglio F, Giodano R, Benso A, Muccioli GP, Deghenghi R, Ghigo E. 1999. Tyr-ala-Hexarelin, a synthetic octapeptide, possess the same endocrine activities of Hexarelin and GHRP-2 in humans. J Endocrinol Invest 22:91-97.
4. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. 1990. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 70:975-982.
5. Box GEP, Cox DR. 1964 An analysis of transformations. J R Stat Soc Ser B 26:211-243.
6. Cella SG, Arce VM, Pieretti F, Locatelli V, Settembrini BP, Muller EE. 1993. Combined administration of growth hormone-releasing hormone and clonidine restores defective growth hormone secretion in old dogs. Neuroendocrinology 57:432-438.
7. Copeland KC, Underwood LE, Van Wyk JJ. 1980. Induction of immunoreactive somatomedin C in human serum by growth hormone: dose-response relationships and effect on chromatographic profiles. J Clin Endocrinol Metab 50:690-697.
8. Copinschi G, Onderbergen AV, L'Hermite-Baleriaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thorner MO, Van Cauter E. 1996. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor 1, and adrenocortical function in normal young men. J Clin Endocrinol Metab 81:2776-2782.
9. Gertz BJ, Barrett JS, Eisenhandler R, Krupa DA, Wittreich JM, Seibild JR, Schneider SH. 1993. Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6. J Clin Endocrinol Metab 77:1393-1397.
10. Hickey G, Jacks TM, Schleim K-D, Frazier E, Chen HY, Krupa D, Feeney W, Nargund RP, Patchett AA, Smith RG. 1997. Repeat administration of the GH-secretagogue MK-0677 increases and maintains elevated IGF-1 levels in beagles. J Endocrinol 152:183-192.
11. Jacks T, Smith R, Judith F, Schleim K, Frazier E, Chen H, Krupa D, Hora D Jr, Nargund R, Patchett A, Hickey G. 1996. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor 1, and other hormonal responses in beagles. Endocrinology 137:5284-5289.
12. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. 1999. Ghrelin is a growth-hormine-rcleasing aceylated peptide from stomach. Nature 402:656-660.
13. Nieman LK, Cutler GB Jr. 1995. Cushing's syndrome. In: DeGroot LJ, editor. Endocrinology, 3rd ed. Philadelphia: W.B. Saunders. p 1741-1769.
14. Patchett AA, Nargund RP, Tata JR, Chen M-H, Barakat KJ, Johnston DBR, Cheng K, Chan WW-S, Butler B, Hickey G, Jacks T, Schleim K, Pong K-K, Chaung L-YP, Chen HY, Frazier E, Leung KH, Chiu S-H, Smith RG. 1995. Design and biological activities of L-163, 191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci USA 92:7001-7005.
15. Pombo M, Harriero J, Penalva A, Peino R, Dieguez C, Casanueva FF. 1995. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. Endocrinology 80:3180-3184.
16. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. 1995. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level. Endocrinology 80:942-947.
17. Schwarz G. 1978. Estimating the dimension of a model. Ann Stat 6: 461-464.
18. Sethumadhaven K, Veeraragavan K, Bowers C. 1991. Demonstration and characterization of the specific binding of growth hormone-releasing peptide to rat anterior pituitary and hypothalamic membranes. Biochem Biophys Res Commun 178:31-37.
19. Smith RG, Pong S-S, Hickey G, Jacks T, Cheng K, Leonard R, Cohen CJ, Arena JP, Chang CH, Drisko J, Wyvratt M, Fisher M, Nargund R, Patchett A. 1996. Modulation of pulsatile GH release through a novel receptor in hypothalamus and pituitary gland. Recent Prog Horm Res 51:261-286.
20. Smith RG, Van der Ploeg LHT, Howard AD, Feghner SD, Cheng K, Hickey GJ, Wyvratt MJ, Fisher MH, Narguno RP, Patchett M. 1997. Peptidomimetic regulation of growth hormone secretion. Endocr Rev 18:621-645.